metformin has been researched along with Male Genitourinary Diseases in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin added to radiotherapy and ADT did not increase rates of ≥ grade 2 gastrointestinal or genitourinary toxicity and is generally safe and well-tolerated." | 3.01 | Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial. ( Ahmed, S; Danielson, B; Dubey, A; Ghosh, S; Hunter, W; Kim, JO; Koul, R; McDonald, MO; Ong, A; Parliament, M; Quon, H; Rowe, L; Sivananthan, G; Usmani, N; Yee, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JO | 1 |
| McDonald, MO | 1 |
| Ong, A | 1 |
| Koul, R | 1 |
| Dubey, A | 1 |
| Hunter, W | 1 |
| Ahmed, S | 1 |
| Quon, H | 1 |
| Yee, D | 1 |
| Parliament, M | 1 |
| Sivananthan, G | 1 |
| Danielson, B | 1 |
| Rowe, L | 1 |
| Ghosh, S | 1 |
| Usmani, N | 1 |
1 trial available for metformin and Male Genitourinary Diseases
| Article | Year |
|---|---|
Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Gastrointestinal Diseases; Humans; Hypoglycemic Agents | 2021 |